Abstract:Immunotherapy with chimeric antigen receptor (CAR)–engineered T cells showed exceptional successes in patients with refractory B cell malignancies. However, first-in-human studies in solid tumors revealed unique hurdles contributing to poor demonstration of efficacy. Understanding the determinants of tumor recognition by CAR T cells should translate into the design of strategies that can overcome resistance. Here, we show that multiple carcinomas express extracellular N-glycans, whose abundance negatively correlates with CAR T cell killing. By knocking out mannoside acetyl-glucosaminyltransferase 5 ( MGAT5 ) in pancreatic adenocarcinoma (PAC), we showed that N-glycans protect tumors from CAR T cell killing by interfering with proper immunological synapse formation and reducing transcriptional activation, cytokine production, and cytotoxicity. To overcome this barrier, we exploited the high metabolic demand of tumors to safely inhibit N-glycans synthesis with the glucose/mannose analog 2-deoxy- d -glucose (2DG). Treatment with 2DG disrupts the N-glycan cover on tumor cells and results in enhanced CAR T cell activity in different xenograft mouse models of PAC. Moreover, 2DG treatment interferes with the PD-1–PD-L1 axis and results in a reduced exhaustion profile of tumor-infiltrating CAR T cells in vivo. The combined 2DG and CAR T cell therapy was successful against multiple carcinomas besides PAC, including those arising from the lung, ovary, and bladder, and with different clinically relevant CAR specificities, such as CD44v6 and CEA. Overall, our results indicate that tumor N-glycosylation regulates the quality and magnitude of CAR T cell responses, paving the way for the rational design of improved therapies against solid malignancies.

Targeting glycans for CAR therapy: The advent of sweet CARs

State of the Art in CAR-T Cell Therapy for Solid Tumors: Is There a Sweeter Future?

Disrupting N-glycan expression on tumor cells boosts chimeric antigen receptor T cell efficacy against solid malignancies

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy

Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors

Targeting cancer-associated glycosylation for adoptive T cell therapy of gastro-intestinal and gynecological cancers

A long way to the battlefront: CAR T cell therapy against solid cancers.

Targeting Tumor-Associated Antigen: A Promising CAR-T Therapeutic Strategy for Glioblastoma Treatment

CAR T cells in solid tumors: challenges and opportunities

Targeted glycan degradation potentiates cellular immunotherapy for solid tumors

New Chimeric Antigen Receptor Design for Solid Tumors

Targeting gastrointestinal cancers with chimeric antigen receptor (CAR)-T cell therapy

Therapeutic targets of armored chimeric antigen receptor T cells navigating the tumor microenvironment

CAR T cells in solid tumors and metastasis: paving the way forward

Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments

Altered cancer metabolism and implications for next-generation CAR T-cell therapies

Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors

Optimising CAR T therapy for the treatment of solid tumors

Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes

Glyco-binding domain chimeric antigen receptors as a new option for cancer immunotherapy